Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Clinical Pharmacology and Therapeutics|May 24, 2012
Effects of CYP induction by rifampicin on tamoxifen exposureL Binkhorst, T van Gelder, W J Loos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2013
Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysisB A M Heemskerk-Gerritsen, M B E Menke-Pluijmers, A Jager, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2015
Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventionsR W F van Leeuwen, F G A Jansman, P M L A van den Bemt, et al.
Journal of Inherited Metabolic Disease|April 24, 2019
A nationwide retrospective observational study of population newborn screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the NetherlandsEmmalie A Jager, Myrthe M Kuijpers, Annet M Bosch, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trialS W Lam, S M de Groot, A H Honkoop, et al.
BMC Biology|September 4, 2023
Personalised modelling of clinical heterogeneity between medium-chain acyl-CoA dehydrogenase patientsChristoff Odendaal, Emmalie A Jager, Anne-Claire M F Martines, et al.
Plos One|May 23, 2015
Repeated nipple fluid aspiration: compliance and feasibility results from a prospective multicenter studyJ S de Groot, C B Moelans, S G Elias, et al.
Breast Cancer Research and Treatment|September 8, 2019
Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?T G Steenbruggen, N I Bouwer, C H Smorenburg, et al.
ESMO Open|February 15, 2025
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancerS M Buijs, M I Mohmaed Ali, E Oomen-de Hoop, et al.
Frontiers in Oncology|July 12, 2021
Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer PatientsI E de Kruijff, A M Sieuwerts, N Beije, et al.
Pageof 7